AdvaMed Code of Ethics®
Achieve the highest levels of compliance with principles on consulting arrangements, training, education and other forms of communications.
My Profile
Member Center
Policy
Top Priorities
On behalf of our members, AdvaMed® works on countless fronts to ensure patients have timely access to life-changing technologies. Find out more about our top policy issues.
Your Featured Resources
Tariff-related Litigation Update – 9/12
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
AdvaMed® Device and Diagnostics Compliance Group Benchmarking | Compliance Training
AdvaMed® periodically compiles benchmarking data on Member companies’ compliance policies regarding travel and lodging for U.S. Health Care Professionals to assist companies in understanding industry trends and practices when the…
Tariff-related Litigation Update – 9/5
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/22
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Tariff-related Litigation Update – 8/15
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Additional Resources
AdvaMed Code of Ethics®
Achieve the highest levels of compliance with principles on consulting arrangements, training, education and other forms of communications.
Tariff-related Litigation Update – 9/12
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
AdvaMed® Device and Diagnostics Compliance Group Benchmarking | Compliance Training
AdvaMed® periodically compiles benchmarking data on Member companies’ compliance policies regarding travel and lodging for U.S. Health Care Professionals to assist companies in understanding industry trends and practices when the…
Tariff-related Litigation Update – 9/5
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Discover More Resources
AdvaMed® members have access to our full library of industry resources.
You are not logged in to the AdvaMed Hub.
AdvaMed Responds to Commerce Department Section 232 National Security Investigation, Seeks Policies to Strengthen U.S. Position as Global Medtech Leader
WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The…
AdvaMed Concludes Largest U.S. MedTech Conference Ever
San Diego—AdvaMed, the Medtech Association, the world’s largest trade association representing medtech innovators, just concluded its most impactful MedTech Conference to date, welcoming 3,708 attendees and representatives from 1,800 companies…
AdvaMed Leads with Integrity: Updated Code of Ethics Now Available
WASHINGTON, D.C. – AdvaMed, the Medtech Association, today announced that its board of directors has unanimously approved revisions to the AdvaMed Code of Ethics on Interactions with Health Care Professionals.
AdvaMed Releases Technical Performance and Safety Bulletin on “Remote Device Operations: Common Challenges and Mitigation Strategies”
WASHINGTON, D.C. – AdvaMed, the Medtech Association, recently published a technical performance and safety bulletin titled, “Remote Device Operations: Common Challenges and Mitigation Strategies” to help health care providers, device…
AdvaMed Statement on Commerce Department Section 232 National Security Investigation
WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into…
AdvaMed Thanks U.S. House Energy and Commerce Health Subcommittee for Highlighting the Need for Medicare Coverage of Breakthrough Medtech
WASHINGTON—AdvaMed, the medtech association, today thanked the U.S. House Energy and Commerce Health Subcommittee for highlighting the need for Medicare coverage of FDA-authorized breakthrough medtech and releasing a discussion draft…
AdvaMed Addresses 2025 APEC Delegates to Promote Common Global Standards for Business Integrity
AdvaMed was honored to address delegates at the 12th Asia-Pacific Economic Cooperation (APEC) Business Ethics for SMEs Forum held in Seoul, Korea, on September 8-9, 2025. AdvaMed galvanized delegates from…
AdvaMed Welcomes Key U.S. House Committee Passage of Breakthrough Medtech Coverage Bill, Urges Addition of Diagnostic Tests
WASHINGTON—AdvaMed, the medtech association, today welcomed U.S. House of Representatives Committee on Ways and Means passage of legislation providing Medicare coverage of FDA-designated and authorized breakthrough medtech. AdvaMed also urged…
AdvaMed Welcomes CMS’ Rural Health Transformation Program
WASHINGTON—AdvaMed, the medtech association, welcomed today’s CMS’ announcement of the details of the $50 billion Rural Health Transformation Program. This program gives states the chance to access the latest health…
Mike Mussallem Named 2025 Medtech Lifetime Achievement Award Winner
Washington, D.C.—Today, AdvaMed, the Medtech Association, announced that Mike Mussallem, former chairman and CEO of Edwards Lifesciences, will receive the 2025 Lifetime Achievement Award at the medtech industry’s premier annual…
Membership Newsletter
We are pleased to provide AdvaMed® members with the Membership Newsletter, a monthly publication designed to communicate relevant news, resources, events and policy updates.